Table 1. Patient baseline characteristics and results of ICGF.
Variable | Value |
---|---|
Age, yrs | 65 [30–87] |
Sex (male/female) | 10/10 |
Disease | |
Primary lung cancer | 15 |
Metastatic lung tumor | 5 |
Smoking history | |
Current/never | 9/11 |
Pulmonary function | |
FEV1, L | 2.25 (1.28–4.02) |
COPD (FEV1% <70) | 5 |
Tumor location | |
Right S2/S3b/S6/S8/S8+9/S8a/7+10+9a | 2/1/1/4/1/1/1 |
Left upper division/upper division +S6/S6 | 6/1/2 |
Tumor size, mm | 16 [9–32] |
Operative duration, min | 186 [90–319] |
Intraoperative blood loss, mL | 30 [0–107] |
Intraoperative adverse events | 0 |
Conversion to thoracotomy | 0 |
Postoperative outcome (Clavien-Dindo classification) | |
Grade 0 | 19 |
Grade I | 1a |
Chest drainage, days | 1 [1–3] |
Hospitalization, days | 5 [5–8] |
ICGF | |
Valid temporary/Invalid demarcation | 19/1 |
First appearance of ICGF, s | 20 [10–100] |
Duration of ICGF, s | 180 [90–300] |
Duration of effective contrast before spread into TSs, s | 70 [30–116] |
Surgical margin | |
≥ Tumor size | 18 |
< Tumor size | 2 |
Data expressed as n (range) unless otherwise indicated. a, slight renal dysfunction. COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; ICGF, indocyanine green fluorescence.